A medical history of presence of chronic bilateral tonic-clonic seizure was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
The individual was admitted with complaints of history of acute bilateral tonic-clonic seizure, progressive hypomimic face detected, progressive focal t2 hyperintense thalamic lesion manifestation, clinical signs of weak voice. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
A medical history of history of focal t2 hyperintense thalamic lesion, presence of moderate hypomimic face was documented. Genetic analysis confirmed gene variant 1868T>G  L623W and 2263A>G K755E. Supportive care and follow-up were recommended.
The patient presented to the clinic with sudden anxiety, intermittent weak voice condition, diagnosed with moderate upgaze palsy. Diagnostic workup revealed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Treatment was initiated accordingly.
The individual was admitted with complaints of history of intermittent decreased liver function, mild weight loss condition, severe bilateral tonic-clonic seizure symptoms, history of upgaze palsy. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
The individual was admitted with complaints of presence of episodic tremor, chronic focal t2 hyperintense thalamic lesion symptoms, diagnosed with moderate decreased liver function. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
The individual was admitted with complaints of history of weak voice, moderate focal t2 hyperintense thalamic lesion, diagnosed with acute decreased liver function. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
The patient presented to the clinic with clinical signs of moderate tremor. Diagnostic workup revealed gene variant W748S and c.3643+2T>C. Treatment was initiated accordingly.
A medical history of weak voice manifestation was documented. Genetic analysis confirmed gene variant c. 2243G>C (p. W748S). Supportive care and follow-up were recommended.
A medical history of history of severe weight loss, history of episodic focal-onset seizure, diagnosed with focal t2 hyperintense thalamic lesion was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
The patient presented to the clinic with acute weak voice detected, history of weight loss, clinical signs of acute tremor. Diagnostic workup revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Treatment was initiated accordingly.
Upon examination, presence of episodic weak voice, moderate weight loss, sudden focal t2 hyperintense thalamic lesion detected, moderate upgaze palsy symptoms were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
Upon examination, episodic hypomimic face manifestation, progressive tremor manifestation, intermittent anxiety condition, acute focal-onset seizure symptoms were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
Upon examination, intermittent weight loss observed, anxiety detected were noted. Further imaging and laboratory tests identified gene variant A467T. The patient was started on a tailored therapeutic plan.
Initial symptoms included diagnosed with sudden weak voice, sudden upgaze palsy detected. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, persistent focal t2 hyperintense thalamic lesion observed, focal-onset seizure detected, intermittent weak voice observed, moderate anxiety observed were noted. Further imaging and laboratory tests identified gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. The patient was started on a tailored therapeutic plan.
Upon examination, presence of severe tremor, chronic hypomimic face manifestation, moderate bilateral tonic-clonic seizure, presence of episodic upgaze palsy were noted. Further imaging and laboratory tests identified gene variant c.3643+1G>A and c.2396C>A (p.S799Y). The patient was started on a tailored therapeutic plan.
Initial symptoms included diagnosed with weight loss, moderate hypomimic face detected. Subsequent investigations showed gene variant p.W748S and p.T914P. Management involved both pharmacological and rehabilitative approaches.
A medical history of diagnosed with sudden weight loss, clinical signs of moderate tremor was documented. Genetic analysis confirmed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Supportive care and follow-up were recommended.
Initial symptoms included chronic weak voice symptoms. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included anxiety detected. Subsequent investigations showed gene variant 1399G >A A467T and 2243G >C W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included persistent weight loss symptoms, intermittent focal-onset seizure observed. Subsequent investigations showed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included presence of weight loss, progressive hypomimic face manifestation, presence of episodic weak voice, diagnosed with intermittent focal-onset seizure. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
Upon examination, history of mild focal t2 hyperintense thalamic lesion, clinical signs of intermittent bilateral tonic-clonic seizure were noted. Further imaging and laboratory tests identified gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with chronic bilateral tonic-clonic seizure manifestation. Diagnostic workup revealed . Treatment was initiated accordingly.
The individual was admitted with complaints of intermittent focal t2 hyperintense thalamic lesion, presence of sudden bilateral tonic-clonic seizure, upgaze palsy symptoms. Laboratory evaluations detected gene variant c.1288A>T and c.2752T>C. Clinical monitoring is ongoing.
Initial symptoms included severe focal t2 hyperintense thalamic lesion detected, history of persistent hypomimic face, acute weak voice observed, diagnosed with chronic anxiety. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with progressive anxiety manifestation, presence of sudden tremor, mild hypomimic face condition. Diagnostic workup revealed gene variant T251I/P587L and R807C. Treatment was initiated accordingly.
The individual was admitted with complaints of clinical signs of focal-onset seizure, severe weight loss detected, episodic hypomimic face. Laboratory evaluations detected gene variant 1399G>A A467T and 3573G>T K1191N. Clinical monitoring is ongoing.
The individual was admitted with complaints of moderate focal t2 hyperintense thalamic lesion. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
A medical history of decreased liver function manifestation, history of intermittent focal-onset seizure, presence of sudden weight loss, severe focal t2 hyperintense thalamic lesion condition was documented. Genetic analysis confirmed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Supportive care and follow-up were recommended.
Initial symptoms included acute tremor manifestation, diagnosed with anxiety. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, acute bilateral tonic-clonic seizure observed were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of severe upgaze palsy. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
The patient presented to the clinic with episodic anxiety, diagnosed with progressive focal-onset seizure, intermittent tremor symptoms, moderate weight loss. Diagnostic workup revealed gene variant P765T. Treatment was initiated accordingly.
The individual was admitted with complaints of presence of sudden tremor, history of mild decreased liver function. Laboratory evaluations detected gene variant W748S and c.3643+2T>C. Clinical monitoring is ongoing.
Initial symptoms included sudden upgaze palsy observed. Subsequent investigations showed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included history of moderate weak voice. Subsequent investigations showed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with intermittent anxiety detected, severe hypomimic face symptoms. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
The patient presented to the clinic with persistent weak voice symptoms, history of mild bilateral tonic-clonic seizure, severe focal-onset seizure manifestation, history of persistent weight loss. Diagnostic workup revealed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Treatment was initiated accordingly.
The individual was admitted with complaints of diagnosed with sudden focal t2 hyperintense thalamic lesion, persistent tremor observed, sudden focal-onset seizure detected, weak voice detected. Laboratory evaluations detected . Clinical monitoring is ongoing.
A medical history of clinical signs of intermittent decreased liver function, intermittent weak voice symptoms, mild hypomimic face manifestation, diagnosed with episodic upgaze palsy was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
A medical history of history of mild anxiety, intermittent focal t2 hyperintense thalamic lesion manifestation, episodic hypomimic face detected, moderate upgaze palsy condition was documented. Genetic analysis confirmed gene variant p.Arg627Gln and p.Arg852Cys. Supportive care and follow-up were recommended.
The individual was admitted with complaints of clinical signs of acute decreased liver function, mild tremor symptoms, diagnosed with anxiety. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
The individual was admitted with complaints of history of severe bilateral tonic-clonic seizure, acute upgaze palsy detected, acute weight loss observed. Laboratory evaluations detected gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Clinical monitoring is ongoing.
Initial symptoms included episodic weak voice, episodic focal t2 hyperintense thalamic lesion condition. Subsequent investigations showed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included mild focal-onset seizure detected, history of episodic upgaze palsy. Subsequent investigations showed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of acute weak voice symptoms. Laboratory evaluations detected gene variant c.2864A>G (p.Tyr955Cys). Clinical monitoring is ongoing.
The individual was admitted with complaints of severe bilateral tonic-clonic seizure, diagnosed with sudden decreased liver function, presence of acute focal-onset seizure, clinical signs of mild anxiety. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
The patient presented to the clinic with history of persistent upgaze palsy, moderate focal t2 hyperintense thalamic lesion observed, clinical signs of intermittent decreased liver function, progressive tremor condition. Diagnostic workup revealed gene variant c.2243G>C p.Trp748Ser. Treatment was initiated accordingly.
Upon examination, acute decreased liver function condition, presence of chronic bilateral tonic-clonic seizure, chronic anxiety symptoms were noted. Further imaging and laboratory tests identified gene variant p.Arg627Gln and p.Arg852Cys. The patient was started on a tailored therapeutic plan.
A medical history of tremor observed, history of severe focal-onset seizure was documented. Genetic analysis confirmed gene variant p.Arg953Cys. Supportive care and follow-up were recommended.
Initial symptoms included severe focal t2 hyperintense thalamic lesion observed, moderate weak voice manifestation. Subsequent investigations showed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Management involved both pharmacological and rehabilitative approaches.
Upon examination, weight loss observed, persistent focal-onset seizure detected, history of chronic upgaze palsy were noted. Further imaging and laboratory tests identified gene variant A467T. The patient was started on a tailored therapeutic plan.
Initial symptoms included history of intermittent tremor, severe weak voice symptoms. Subsequent investigations showed gene variant p.Arg627Gln and p.Arg852Cys. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with clinical signs of severe focal t2 hyperintense thalamic lesion, acute focal-onset seizure, chronic weak voice manifestation, upgaze palsy. Diagnostic workup revealed . Treatment was initiated accordingly.
Initial symptoms included chronic hypomimic face observed, diagnosed with sudden tremor. Subsequent investigations showed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included mild weight loss detected. Subsequent investigations showed gene variant p.A467T and c.2157+5_6GC>AG. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of decreased liver function. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
A medical history of progressive tremor manifestation, clinical signs of episodic hypomimic face, persistent weight loss manifestation was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
Upon examination, intermittent upgaze palsy detected, history of acute focal t2 hyperintense thalamic lesion, history of intermittent bilateral tonic-clonic seizure, diagnosed with acute weight loss were noted. Further imaging and laboratory tests identified gene variant c.2864A>G (p.Tyr955Cys). The patient was started on a tailored therapeutic plan.
A medical history of diagnosed with weight loss, presence of severe weak voice was documented. Genetic analysis confirmed gene variant c.2243G>C. Supportive care and follow-up were recommended.
A medical history of diagnosed with acute decreased liver function was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
Initial symptoms included presence of chronic focal t2 hyperintense thalamic lesion, diagnosed with progressive weak voice, progressive weight loss detected. Subsequent investigations showed gene variant Tyr955Cys. Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of severe decreased liver function, progressive focal t2 hyperintense thalamic lesion condition, history of moderate weak voice was documented. Genetic analysis confirmed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Supportive care and follow-up were recommended.
The patient presented to the clinic with focal t2 hyperintense thalamic lesion, presence of progressive focal-onset seizure, severe tremor manifestation, presence of episodic hypomimic face. Diagnostic workup revealed gene variant p.Arg953Cys. Treatment was initiated accordingly.
The patient presented to the clinic with sudden weak voice, presence of persistent focal t2 hyperintense thalamic lesion, chronic decreased liver function condition. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of clinical signs of mild tremor, episodic upgaze palsy symptoms, chronic hypomimic face manifestation. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
Initial symptoms included history of intermittent decreased liver function. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Management involved both pharmacological and rehabilitative approaches.
Upon examination, mild tremor symptoms were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of diagnosed with tremor, clinical signs of mild anxiety. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
A medical history of diagnosed with chronic weight loss, moderate bilateral tonic-clonic seizure symptoms was documented. Genetic analysis confirmed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Supportive care and follow-up were recommended.
Upon examination, severe weak voice condition, diagnosed with mild tremor were noted. Further imaging and laboratory tests identified gene variant Tyr955Cys. The patient was started on a tailored therapeutic plan.
Upon examination, tremor manifestation, clinical signs of moderate anxiety were noted. Further imaging and laboratory tests identified gene variant c.2864A>G (p.Tyr955Cys). The patient was started on a tailored therapeutic plan.
Upon examination, sudden weak voice symptoms were noted. Further imaging and laboratory tests identified gene variant p.A467T and c.2157+5_6GC>AG. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of progressive anxiety, sudden bilateral tonic-clonic seizure. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
A medical history of history of moderate decreased liver function, focal-onset seizure manifestation, chronic weak voice, severe weight loss symptoms was documented. Genetic analysis confirmed gene variant 1399G >A A467T and 2243G >C W748S. Supportive care and follow-up were recommended.
A medical history of diagnosed with acute hypomimic face was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
A medical history of diagnosed with chronic focal-onset seizure, diagnosed with mild upgaze palsy, moderate decreased liver function manifestation, diagnosed with sudden weight loss was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
Upon examination, acute tremor were noted. Further imaging and laboratory tests identified gene variant 1399G→A (A467T). The patient was started on a tailored therapeutic plan.
Initial symptoms included intermittent bilateral tonic-clonic seizure observed. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, intermittent anxiety symptoms were noted. Further imaging and laboratory tests identified gene variant 1868T>G  L623W and 2263A>G K755E. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of severe weak voice condition, history of sudden upgaze palsy, presence of moderate anxiety. Laboratory evaluations detected gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Clinical monitoring is ongoing.
Upon examination, presence of sudden decreased liver function were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
Upon examination, persistent anxiety manifestation, persistent tremor detected were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with diagnosed with acute anxiety, mild weight loss, diagnosed with sudden focal t2 hyperintense thalamic lesion, clinical signs of chronic upgaze palsy. Diagnostic workup revealed gene variant p.Arg627Gln and p.Arg852Cys. Treatment was initiated accordingly.
A medical history of moderate focal-onset seizure manifestation, intermittent weight loss symptoms, progressive hypomimic face detected was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
Upon examination, clinical signs of bilateral tonic-clonic seizure, clinical signs of severe weak voice, history of severe upgaze palsy were noted. Further imaging and laboratory tests identified gene variant c.2864A>G (p.Tyr955Cys). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of weight loss observed. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
Initial symptoms included presence of mild upgaze palsy. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included severe weak voice condition, history of sudden bilateral tonic-clonic seizure. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of bilateral tonic-clonic seizure symptoms, chronic weight loss manifestation, severe anxiety detected. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
Initial symptoms included episodic focal-onset seizure manifestation. Subsequent investigations showed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Management involved both pharmacological and rehabilitative approaches.
A medical history of acute weight loss condition was documented. Genetic analysis confirmed gene variant C752T (T251I) and C1760T (P587L). Supportive care and follow-up were recommended.
The individual was admitted with complaints of persistent upgaze palsy symptoms, chronic focal-onset seizure manifestation, clinical signs of progressive weak voice. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
Upon examination, clinical signs of bilateral tonic-clonic seizure, presence of acute focal t2 hyperintense thalamic lesion were noted. Further imaging and laboratory tests identified gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of clinical signs of persistent weight loss. Laboratory evaluations detected gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Clinical monitoring is ongoing.
The patient presented to the clinic with intermittent hypomimic face manifestation, clinical signs of acute focal-onset seizure. Diagnostic workup revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Treatment was initiated accordingly.
The individual was admitted with complaints of moderate weak voice. Laboratory evaluations detected gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Clinical monitoring is ongoing.
The individual was admitted with complaints of diagnosed with episodic bilateral tonic-clonic seizure, diagnosed with chronic weak voice. Laboratory evaluations detected gene variant p.Arg953Cys. Clinical monitoring is ongoing.
A medical history of decreased liver function manifestation was documented. Genetic analysis confirmed gene variant c.2864A>G (p.Tyr955Cys). Supportive care and follow-up were recommended.
The patient presented to the clinic with acute focal t2 hyperintense thalamic lesion detected, episodic decreased liver function observed, history of chronic weak voice, history of intermittent hypomimic face. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
Initial symptoms included diagnosed with progressive tremor, persistent weight loss, progressive focal-onset seizure symptoms, clinical signs of sudden bilateral tonic-clonic seizure. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included severe weight loss symptoms, episodic focal t2 hyperintense thalamic lesion condition, sudden anxiety observed, severe tremor detected. Subsequent investigations showed gene variant 1399G→A (A467T). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included presence of moderate hypomimic face, weight loss manifestation, clinical signs of persistent tremor. Subsequent investigations showed gene variant c.2243G>C p.Trp748Ser. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of decreased liver function, clinical signs of persistent weight loss. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
A medical history of mild bilateral tonic-clonic seizure, episodic focal t2 hyperintense thalamic lesion condition, history of episodic focal-onset seizure was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
A medical history of sudden hypomimic face manifestation, acute focal t2 hyperintense thalamic lesion manifestation, intermittent weak voice symptoms, episodic tremor symptoms was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
A medical history of persistent anxiety symptoms, upgaze palsy detected, history of mild decreased liver function was documented. Genetic analysis confirmed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Supportive care and follow-up were recommended.
The individual was admitted with complaints of decreased liver function detected, mild weak voice. Laboratory evaluations detected gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Clinical monitoring is ongoing.
Initial symptoms included bilateral tonic-clonic seizure. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included moderate decreased liver function condition, moderate tremor observed. Subsequent investigations showed gene variant c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
A medical history of anxiety manifestation, clinical signs of sudden decreased liver function was documented. Genetic analysis confirmed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Supportive care and follow-up were recommended.
The patient presented to the clinic with clinical signs of acute focal-onset seizure, acute weight loss detected. Diagnostic workup revealed gene variant W748S. Treatment was initiated accordingly.
The patient presented to the clinic with mild decreased liver function observed. Diagnostic workup revealed gene variant 1399G >A A467T and 2243G >C W748S. Treatment was initiated accordingly.
Initial symptoms included presence of upgaze palsy, severe decreased liver function manifestation, episodic tremor symptoms, diagnosed with sudden focal t2 hyperintense thalamic lesion. Subsequent investigations showed gene variant 1868T>G  L623W and 2263A>G K755E. Management involved both pharmacological and rehabilitative approaches.
A medical history of severe tremor manifestation, diagnosed with progressive anxiety was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
Initial symptoms included presence of weight loss, history of severe hypomimic face, presence of mild decreased liver function. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included acute upgaze palsy detected, clinical signs of sudden hypomimic face, clinical signs of sudden decreased liver function, moderate tremor manifestation. Subsequent investigations showed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of sudden weight loss, persistent anxiety condition, focal-onset seizure symptoms, diagnosed with mild hypomimic face. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
Upon examination, presence of episodic decreased liver function, sudden focal-onset seizure condition, history of acute bilateral tonic-clonic seizure, sudden tremor symptoms were noted. Further imaging and laboratory tests identified gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. The patient was started on a tailored therapeutic plan.
A medical history of presence of acute decreased liver function, history of mild upgaze palsy, history of episodic weight loss was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
A medical history of diagnosed with progressive bilateral tonic-clonic seizure was documented. Genetic analysis confirmed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Supportive care and follow-up were recommended.
A medical history of progressive hypomimic face, diagnosed with sudden bilateral tonic-clonic seizure, history of persistent upgaze palsy, persistent decreased liver function observed was documented. Genetic analysis confirmed gene variant c. 2243G>C (p. W748S). Supportive care and follow-up were recommended.
The patient presented to the clinic with intermittent decreased liver function symptoms, presence of episodic weak voice. Diagnostic workup revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Treatment was initiated accordingly.
The individual was admitted with complaints of intermittent focal t2 hyperintense thalamic lesion manifestation. Laboratory evaluations detected gene variant W748S and c.3643+2T>C. Clinical monitoring is ongoing.
The patient presented to the clinic with presence of sudden weak voice. Diagnostic workup revealed gene variant c.3286C>T (p.Arg1096Cys). Treatment was initiated accordingly.
Upon examination, chronic anxiety detected, progressive weight loss detected, clinical signs of mild focal t2 hyperintense thalamic lesion were noted. Further imaging and laboratory tests identified gene variant c3239G>C p.Ser1080Thr. The patient was started on a tailored therapeutic plan.
Upon examination, episodic decreased liver function symptoms were noted. Further imaging and laboratory tests identified gene variant c.2243G>C. The patient was started on a tailored therapeutic plan.
Upon examination, chronic focal t2 hyperintense thalamic lesion condition, episodic weight loss detected were noted. Further imaging and laboratory tests identified gene variant c.752C>T p.T251I and c.1760C>T p.P587L. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of history of persistent upgaze palsy, sudden focal-onset seizure, weak voice symptoms. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
Upon examination, intermittent anxiety manifestation, progressive tremor, bilateral tonic-clonic seizure detected, sudden focal-onset seizure observed were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
Initial symptoms included chronic hypomimic face manifestation. Subsequent investigations showed gene variant c.2243G>C. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of acute anxiety. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
Upon examination, diagnosed with intermittent focal-onset seizure, anxiety observed, intermittent decreased liver function observed were noted. Further imaging and laboratory tests identified gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. The patient was started on a tailored therapeutic plan.
A medical history of sudden upgaze palsy, progressive tremor symptoms, clinical signs of progressive anxiety was documented. Genetic analysis confirmed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Supportive care and follow-up were recommended.
The individual was admitted with complaints of episodic upgaze palsy observed, mild tremor condition, persistent focal-onset seizure observed. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
Upon examination, presence of sudden tremor, persistent bilateral tonic-clonic seizure manifestation, intermittent focal-onset seizure were noted. Further imaging and laboratory tests identified gene variant c.752C>T p.T251I and c.1760C>T p.P587L. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with acute anxiety, moderate hypomimic face observed, clinical signs of episodic decreased liver function. Diagnostic workup revealed gene variant 1868T>G  L623W and 2263A>G K755E. Treatment was initiated accordingly.
Upon examination, history of moderate decreased liver function were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
Initial symptoms included severe focal-onset seizure condition, presence of episodic weight loss, moderate bilateral tonic-clonic seizure symptoms. Subsequent investigations showed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with presence of mild focal t2 hyperintense thalamic lesion, history of moderate hypomimic face, moderate decreased liver function detected, clinical signs of moderate tremor. Diagnostic workup revealed gene variant c.2243G>C. Treatment was initiated accordingly.
Initial symptoms included severe weight loss observed, presence of focal t2 hyperintense thalamic lesion, clinical signs of intermittent focal-onset seizure, acute bilateral tonic-clonic seizure. Subsequent investigations showed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Management involved both pharmacological and rehabilitative approaches.
Upon examination, mild weak voice, intermittent bilateral tonic-clonic seizure detected were noted. Further imaging and laboratory tests identified gene variant W748S. The patient was started on a tailored therapeutic plan.
Initial symptoms included history of mild focal t2 hyperintense thalamic lesion, acute focal-onset seizure condition. Subsequent investigations showed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with mild focal-onset seizure manifestation, episodic weight loss detected. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
Initial symptoms included intermittent hypomimic face manifestation, history of acute upgaze palsy, bilateral tonic-clonic seizure detected. Subsequent investigations showed gene variant 1399G >A A467T and 2243G >C W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of progressive decreased liver function, intermittent focal t2 hyperintense thalamic lesion observed, moderate focal-onset seizure condition, sudden weak voice symptoms. Laboratory evaluations detected . Clinical monitoring is ongoing.
Initial symptoms included presence of focal-onset seizure. Subsequent investigations showed gene variant C752T (T251I) and C1760T (P587L). Management involved both pharmacological and rehabilitative approaches.
Upon examination, progressive focal t2 hyperintense thalamic lesion condition were noted. Further imaging and laboratory tests identified gene variant c. 2243G>C (p. W748S). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of sudden anxiety observed, episodic bilateral tonic-clonic seizure detected. Laboratory evaluations detected gene variant T251I/P587L and R807C. Clinical monitoring is ongoing.
The patient presented to the clinic with mild focal t2 hyperintense thalamic lesion condition, presence of intermittent focal-onset seizure, presence of chronic bilateral tonic-clonic seizure. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The patient presented to the clinic with clinical signs of persistent tremor, episodic focal t2 hyperintense thalamic lesion detected. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
The patient presented to the clinic with tremor manifestation, mild bilateral tonic-clonic seizure detected. Diagnostic workup revealed gene variant c. 2243G>C (p. W748S). Treatment was initiated accordingly.
Initial symptoms included presence of persistent tremor, sudden anxiety condition, progressive weak voice symptoms, chronic bilateral tonic-clonic seizure detected. Subsequent investigations showed gene variant P765T. Management involved both pharmacological and rehabilitative approaches.
A medical history of progressive focal t2 hyperintense thalamic lesion condition, moderate hypomimic face, progressive anxiety detected, presence of severe bilateral tonic-clonic seizure was documented. Genetic analysis confirmed gene variant c3239G>C p.Ser1080Thr. Supportive care and follow-up were recommended.
The individual was admitted with complaints of sudden tremor observed, chronic decreased liver function symptoms, acute anxiety manifestation. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
Initial symptoms included severe weight loss condition. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
Upon examination, focal t2 hyperintense thalamic lesion observed, presence of acute decreased liver function were noted. Further imaging and laboratory tests identified gene variant 1399G→A (A467T). The patient was started on a tailored therapeutic plan.
Initial symptoms included clinical signs of persistent weight loss, diagnosed with progressive focal-onset seizure. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of moderate hypomimic face, progressive weight loss symptoms. Laboratory evaluations detected gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
The patient presented to the clinic with moderate anxiety manifestation, history of chronic hypomimic face, progressive focal-onset seizure observed. Diagnostic workup revealed gene variant p.A467T and c.2157+5_6GC>AG. Treatment was initiated accordingly.
A medical history of severe anxiety condition, sudden focal-onset seizure detected, clinical signs of sudden decreased liver function, clinical signs of moderate hypomimic face was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
The individual was admitted with complaints of history of moderate focal-onset seizure, history of sudden tremor. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
Initial symptoms included acute weight loss manifestation, diagnosed with severe focal-onset seizure, moderate weak voice detected, moderate tremor symptoms. Subsequent investigations showed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included clinical signs of chronic focal-onset seizure, diagnosed with weak voice, history of persistent bilateral tonic-clonic seizure, episodic decreased liver function detected. Subsequent investigations showed gene variant W748S and c.3643+2T>C. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of presence of sudden focal-onset seizure, clinical signs of episodic weak voice. Laboratory evaluations detected gene variant c.2243G>C p.Trp748Ser. Clinical monitoring is ongoing.
A medical history of acute decreased liver function manifestation was documented. Genetic analysis confirmed gene variant 1399G>A A467T and 3573G>T K1191N. Supportive care and follow-up were recommended.
A medical history of diagnosed with moderate weight loss, diagnosed with severe anxiety, severe focal-onset seizure observed, mild focal t2 hyperintense thalamic lesion observed was documented. Genetic analysis confirmed gene variant 1399G >A A467T and 2243G >C W748S. Supportive care and follow-up were recommended.
A medical history of sudden weak voice symptoms, presence of severe bilateral tonic-clonic seizure, progressive hypomimic face detected was documented. Genetic analysis confirmed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Supportive care and follow-up were recommended.
The individual was admitted with complaints of presence of episodic anxiety, presence of mild tremor. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
The patient presented to the clinic with chronic bilateral tonic-clonic seizure, history of mild weak voice. Diagnostic workup revealed gene variant C752T (T251I) and C1760T (P587L). Treatment was initiated accordingly.
The patient presented to the clinic with persistent tremor symptoms, acute bilateral tonic-clonic seizure observed, diagnosed with intermittent anxiety. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The patient presented to the clinic with severe upgaze palsy. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
The patient presented to the clinic with persistent tremor, acute weak voice condition. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
A medical history of history of intermittent bilateral tonic-clonic seizure, history of focal t2 hyperintense thalamic lesion, persistent hypomimic face observed was documented. Genetic analysis confirmed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Supportive care and follow-up were recommended.
Initial symptoms included clinical signs of mild anxiety. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
A medical history of history of chronic focal-onset seizure was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
A medical history of mild focal-onset seizure was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
The individual was admitted with complaints of episodic anxiety observed, episodic upgaze palsy manifestation. Laboratory evaluations detected . Clinical monitoring is ongoing.
The patient presented to the clinic with presence of mild decreased liver function, history of mild upgaze palsy, clinical signs of progressive focal t2 hyperintense thalamic lesion. Diagnostic workup revealed gene variant W748S. Treatment was initiated accordingly.
A medical history of intermittent focal-onset seizure detected, moderate focal t2 hyperintense thalamic lesion observed was documented. Genetic analysis confirmed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Supportive care and follow-up were recommended.
Initial symptoms included clinical signs of severe focal t2 hyperintense thalamic lesion, presence of weight loss, weak voice detected. Subsequent investigations showed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Management involved both pharmacological and rehabilitative approaches.
A medical history of episodic anxiety symptoms, mild weak voice was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
The individual was admitted with complaints of diagnosed with acute focal t2 hyperintense thalamic lesion. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
Initial symptoms included presence of intermittent weak voice, tremor symptoms. Subsequent investigations showed gene variant Tyr955Cys. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included clinical signs of severe upgaze palsy, diagnosed with episodic tremor, history of acute weight loss. Subsequent investigations showed gene variant Tyr955Cys. Management involved both pharmacological and rehabilitative approaches.
Upon examination, history of episodic weight loss, sudden anxiety manifestation, history of severe tremor were noted. Further imaging and laboratory tests identified gene variant c.679C>T p.R227W and c.2542G>A p.G848S. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of mild decreased liver function condition, severe focal t2 hyperintense thalamic lesion observed, presence of persistent bilateral tonic-clonic seizure, moderate focal-onset seizure manifestation. Laboratory evaluations detected gene variant 1868T>G  L623W and 2263A>G K755E. Clinical monitoring is ongoing.
Upon examination, anxiety symptoms, diagnosed with weak voice, moderate tremor, moderate hypomimic face manifestation were noted. Further imaging and laboratory tests identified gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. The patient was started on a tailored therapeutic plan.
Initial symptoms included presence of severe tremor. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with mild anxiety condition, clinical signs of sudden hypomimic face, severe bilateral tonic-clonic seizure. Diagnostic workup revealed gene variant W748S and c.3643+2T>C. Treatment was initiated accordingly.
Upon examination, progressive weak voice observed were noted. Further imaging and laboratory tests identified gene variant c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of presence of mild focal t2 hyperintense thalamic lesion, progressive upgaze palsy manifestation, severe decreased liver function detected, clinical signs of progressive hypomimic face. Laboratory evaluations detected gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Clinical monitoring is ongoing.
Upon examination, clinical signs of sudden weight loss, chronic decreased liver function symptoms, progressive hypomimic face detected were noted. Further imaging and laboratory tests identified gene variant A467T. The patient was started on a tailored therapeutic plan.
Initial symptoms included mild weak voice, diagnosed with sudden weight loss, severe tremor detected, progressive hypomimic face symptoms. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with intermittent weak voice detected. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
A medical history of history of moderate bilateral tonic-clonic seizure, intermittent weight loss condition, sudden focal-onset seizure symptoms was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
Initial symptoms included persistent focal t2 hyperintense thalamic lesion manifestation, moderate hypomimic face. Subsequent investigations showed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of diagnosed with acute anxiety. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
